Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-HSD #1
- Development stage
- Preclinical
- Lead developer
- Aligos Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALG-HSD #1 is a preclinical GalNAc-conjugated small interfering RNA (siRNA) candidate designed to selectively silence the expression of 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) in hepatocytes. Developed by Aligos Therapeutics in collaboration with Merck & Co., the therapeutic is being investigated for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). By targeting HSD17B13, a liver-enriched lipid droplet-associated protein linked to liver inflammation and injury, ALG-HSD #1 aims to mimic the protective effects of loss-of-function genetic variants. In preclinical models, including non-human primates, the candidate has demonstrated robust and durable knockdown of HSD17B13 mRNA and protein levels with a favorable safety profile.
- Other names
- ALG-HSD 1ALG-HSD1ALG-HSD-1
02
Targets
HSD17B13 (17β-Hydroxysteroid Dehydrogenase Type 13)
Beyond the preview
Go deeper on ALG-HSD #1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-HSD #1.